Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:32 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,232 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed Phase 1 Interventional

An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates

NCT00760279
View directory record Official record
Conditions
Ureaplasma, Bacterial Infection
Interventions
Azithromycin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 30 Days
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Nov 2, 2026, 6:32 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Transparent Elastomeric Respirator for Aerosol-based Protection

NCT04511390
View directory record Official record
Conditions
Personal Protective Equipment
Interventions
Transparent, reusable respirator
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Nov 2, 2026, 6:32 PM EST
Withdrawn Not applicable Interventional

Negative Pressure Wound Therapy for Surgical Site Infection Prevention in Common Femoral Artery Exposure

NCT03935659
View directory record Official record
Conditions
Surgical Site Infection, Groin Infections
Interventions
Negative Pressure Pressure Wound Therapy, Standard Wound Care
Device · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Nov 2, 2026, 6:32 PM EST
Not listed Phase 1 Interventional

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

NCT02134392
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Jonathan Gisser
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 2, 2026, 6:32 PM EST
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 6:32 PM EST
Recruiting Early Phase 1 Interventional

Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis

NCT07039019
View directory record Official record
Conditions
Pleuritis, Non-specific
Interventions
Corticosteroid, No Corticosteroid
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Nov 2, 2026, 6:32 PM EST
Completed No phase listed Observational

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

NCT04682548
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Nov 2, 2026, 6:32 PM EST
Withdrawn No phase listed Observational

2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies

NCT01270685
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

NCT03069365
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Nov 2, 2026, 6:32 PM EST
Completed No phase listed Observational

Early Short Course Corticosteroids in COVID-19

NCT04374071
View directory record Official record
Conditions
COVID, Pneumonia, Viral
Interventions
Methylprednisolone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 3 Interventional

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

NCT00078663
View directory record Official record
Conditions
Critical Illness
Interventions
Oral Care
Behavioral
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 2, 2026, 6:32 PM EST
Active, not recruiting No phase listed Observational

Artoss Prospective Spine Registry Outcomes

NCT04439032
View directory record Official record
Conditions
Spinal Fusion
Interventions
NanoBone Bone Graft Substitute
Other
Lead sponsor
Artoss Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Timeline
2020 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Tempe, Arizona • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Nov 2, 2026, 6:32 PM EST
Not listed Phase 4 Interventional

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

NCT00740064
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Abacavir/Lamivudine
Drug
Lead sponsor
Denver Infectious Disease Consultants, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Denver, Colorado • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 1 Interventional

Phase I Trial of S-1153 in Patients With HIV Infection

NCT00002214
View directory record Official record
Conditions
HIV Infections
Interventions
Capravirine
Drug
Lead sponsor
Lexigen Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

NCT00584844
View directory record Official record
Conditions
Tularemia
Interventions
Live F tularensis Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
17 Years to 65 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Nov 2, 2026, 6:32 PM EST
Not listed Phase 1 Interventional

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

NCT02600793
View directory record Official record
Conditions
Cerebrospinal Fluid Shunts, Ventriculoperitoneal Shunt
Interventions
Ceftaroline
Drug
Lead sponsor
Basim Asmar
Other
Eligibility
6 Months to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Nov 2, 2026, 6:32 PM EST
Completed No phase listed Observational

Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias

NCT01144793
View directory record Official record
Conditions
Leukemia, Lymphocytic, Leukemia, Myeloid
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Nov 2, 2026, 6:32 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Urinary Cytokines in Patients With Overactive Bladder (OAB)

NCT00868621
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infection
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 2, 2026, 6:32 PM EST
Completed Phase 1 Interventional Results available

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, HXTC
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Nov 2, 2026, 6:32 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Adaptability of an Undetectable = Untransmissible Model for HBV

NCT07449091
View directory record Official record
Conditions
Chronic Hepatitis b, Viremia
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 2, 2026, 6:32 PM EST